UPDATE : Sunday, February 23, 2020
HOME Policy
New drug re-evaluation requires global sales, approval reports
  • By Lee Hye-seon
  • Published 2017.11.22 11:07
  • Updated 2017.11.22 11:07
  • comments 0

The Ministry of Food and Drug Safety said Tuesday pharmaceutical companies applying for the re-evaluation of new drugs should submit reports on their safety, sales, and approval status on a global scale.

The ministry issued a public notice about a revised version of “Criteria for Re-evaluation of New Drugs.”

According to the revision, a company holding the government’s approval on its new drug should estimate the first sales of the drug during the re-evaluation period. Within three months after the completion of the estimation, the company ought to submit a report that includes the first sales results, analysis, and evaluation of the first sales.

The re-evaluation will also need reports on the drug’s safety and sales status in and outside of Korea. A company with a sales license should submit a safety report based on local and overseas documents and research papers, which should include adverse drug reactions.

The revised criteria went into effect upon the announcement.


<© Korea Biomedical Review, All rights reserved.>

Other articles by Lee Hye-seon
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top